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METHODOLOGY Open Access
Developing clinical practice guidelines: types of
evidence and outcomes; values and economics,
synthesis, grading, and presentation and deriving
recommendations
Steven Woolf1, Holger J Schünemann2, Martin P Eccles3, Jeremy M Grimshaw4,5 and Paul Shekelle6,7*
Abstract
Clinical practice guidelines are one of the foundations of efforts to improve healthcare. In 1999, we authored a
paper about methods to develop guidelines. Since it was published, the methods of guideline development have
progressed both in terms of methods and necessary procedures and the context for guideline development has
changed with the emergence of guideline clearinghouses and large scale guideline production organisations (such
as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three
articles, update and extend our earlier paper. In this second paper, we discuss issues of identifying and synthesizing
evidence: deciding what type of evidence and outcomes to include in guidelines; integrating values into a
guideline; incorporating economic considerations; synthesis, grading, and presentation of evidence; and moving
from evidence to recommendations.
Background
Clinical practice guidelines (hereafter referred to as guide-
lines) are one of the foundations of efforts to improve
healthcare. The modern age of guidelines began with a
1992 Institute of Medicine (IOM) report, which defined
guidelines as ‘systematically developed statements to assist
practitioner and patient decisions about appropriate
healthcare for specific clinical circumstances’ [1]. In 1999,
we authored a paper about methods to develop guidelines
[2]. It covered: identifying and refining the subject area of
the guideline; running guideline development groups;
identifying and assessing the evidence; translating evi-
dence into a clinical practice guideline; and reviewing and
updating guidelines. Since it was published, the methods
of guideline development have progressed both in terms
of methods and necessary procedures and the broad con-
text for clinical practice guidelines has changed.
To help users identify and choose guidelines there has
been the emergence of guideline clearing houses (such
as the US Agency for Healthcare Research and Quality
(AHRQ) Guideline Clearing House, www.guideline.gov)
that identify and systematically characterize guidelines
on a number of domains and the development of robust
guideline appraisal instruments such as the AGREE tool
[3,4]. There has been the appearance of large-scale
guideline production organisations both at a national
level (such as the UK National Institute for Health and
Clinical Excellence or Scottish Intercollegiate Guidelines
Network) and a condition level (such as the Ontario
Cancer Guideline Program). There have also been rele-
vant reports (that some of us have participated in) for
the World Health Organisation [5] and professional
societies (Schünemann HJ, Woodhead M, Anzueto A,
Buist AS, MacNee W, Rabe KF, Heffner J. A guide for
guidelines for professional societies and other developers
of recommendations: an official American Thoracic Society
(ATS) / European Respiratory Society (ERS) Workshop
Report; in preparation). Such organizations and those
interested in producing and using guidelines now have a
high profile society in the Guidelines International
Network (http://www.g-i-n.net/). Against this background
it seems timely to, in a series of three articles, update and
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extend our earlier paper on the methods of developing
clinical practice guidelines. This series is based on a back-
ground paper [6] we prepared for the IOM report ‘Clinical
Practice Guidelines We Can Trust’ [7].
In the first paper, we discussed target audience(s) for
guidelines, identifying topics for guidelines, guideline
group composition, and the processes by which guide-
line groups function and the important procedural issue
of conflicts of interest. In this second paper, we move on
to discuss issues of identifying and synthesizing evi-
dence: deciding what type of evidence and outcomes to
include in guidelines; integrating values into a guideline;
incorporating economic considerations; synthesis, grad-
ing, and presentation of evidence; and moving from evi-
dence to recommendations. In the third paper, we will
discuss the issues of: reviewing, reporting, and publish-
ing guidelines; updating guidelines; and the two emer-
ging issues of enhancing guideline implementability and
how guidelines approach dealing with patients with co-
morbid conditions.
Deciding what type of evidence and outcomes to
include in guidelines
Guidelines typically consider different clinical questions
including: the identification of risk factors for conditions;
diagnostic criteria for conditions; prognostic factors with
and without treatment; the benefits and harms of differ-
ent treatment options; the resources associated with dif-
ferent diagnostic or treatment options; and patients’
experiences of healthcare interventions. Different study
designs provide the most reliable types of evidence for
these different questions. Addressing this has implica-
tions for the conduct (searching, appraising, and synthe-
sizing stages) of knowledge syntheses being undertaken
to inform guideline recommendations. Important princi-
ples at this stage of guideline development include the
need for guideline developers to make explicit decisions
at the outset of the analytic process regarding the spe-
cific questions to be answered and the outcomes to be
assessed, to have a clear understanding of the analytic
logic of the recommendations, to use this model for
keeping the analytic work of the group ‘on track,’ to be
explicit about the types of evidence or opinion that sup-
port each component of the analytic logic, and to trans-
mit this information clearly to the reader in the rationale
statement of the guideline. Any model that achieves
these organizational principles serves the purpose of an
analytic framework [8-13].
Developing an analytical framework
The analytic framework of a guideline is a key element
in guideline development. It is in this critical stage that a
group defines which questions must be answered to ar-
rive at a recommendation, which types of evidence and
information are relevant to the analysis, and by what cri-
teria that evidence will be evaluated. The analytic work
encompasses the examination of scientific evidence, ex-
pert opinion, clinical experience, and other relevant in-
formation and the use of decision rules to translate that
information into recommendations. The end product of
the process is captured in the analytic logic of the guide-
line, the rationale for the recommendations.
Defining the analytic framework
The first step is to define the key questions. What infor-
mation is required by the group to arrive at a recom-
mendation? It begins with defining the criteria that must
be met to convince the group that a clinical behavior
should be advocated. The potential options depend on
the viewpoint of the group and the nature of the topic.
Some groups base the decision on current practice pat-
terns or on opinions drawn from consensus or clinical
experience. Many groups base the decision on scientific
evidence, but they often differ in how they define effect-
iveness. Benefits can be defined by various measures of
morbidity and mortality. Some groups consider benefits
alone, and others consider adverse effects, costs, and
other outcomes. It is therefore important for guideline
developers to be as explicit as possible in defining out-
comes of interest. It is not enough to state that the
practice should be ‘clinically effective.’ What specific
outcomes need to be affected to arrive at a recommen-
dation? The group should decide which health, inter-
mediate, and surrogate outcomes will be considered.
A health outcome refers to direct measures of health
status, including measures of physical morbidity (e.g.,
dyspnea, blindness, weakness), emotional well-being,
and mortality (e.g., survival, life expectancy). Eddy
defines these as ‘outcomes that people can experience
(feel physically or mentally) and care about’ [8]. An
intermediate outcome is an effect that leads to a health
outcome, and a surrogate outcome is an effect that is
equivalent to a health outcome or can act as its proxy.
Intermediate and surrogate outcomes are often physio-
logic variables, test results, or other measures that do
not qualify as health outcomes by themselves but that
have established pathophysiologic relationships with
these outcomes. For coronary angioplasty, the establish-
ment of arterial patency is an intermediate outcome
leading to the desired health outcome of preventing sub-
sequent ischemia. Surrogate outcomes could include
electrocardiographic changes as a surrogate for cardiac
ischemia, serum creatinine concentration for renal insuf-
ficiency, and pulmonary function tests for obstructive
pulmonary disease. Although intermediate and surrogate
outcomes are clearly less persuasive indices than actual
health outcomes, they are often used in the analytic
process because they are frequently the only validated
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outcome measures available in existing research. Guide-
line developers should determine which of these out-
comes must be affected to convince the group that the
maneuver should be recommended.
The potentially complex interrelationships between
these outcomes are best visualized in a graphic or tabu-
lar format. A recent example of an analytic framework is
shown in Figure 1, developed by the U.S. Preventive
Services Task Force when considering a guideline about
screening for osteoporosis [14]. This diagrammatic ap-
proach, first described in the late 1980s, emerged from
earlier work on causal pathways [10], causal models [11],
influence diagrams [12], and evidence models [13]. The
construction of the diagram begins with listing the out-
comes that the group has identified as important. This list
of benefits, harms, and other outcomes reflects the key
criteria that the group must address in its analytic process
to assess appropriateness and arrive at a recommendation.
Intermediate or surrogate outcomes that the group con-
siders valid markers of effectiveness are next added to the
diagram. The interconnecting lines, or linkages, that ap-
pear in Figure 1 represent the critical premises in the ana-
lytic logic that must be confirmed by the review process
to support the recommendation. KQ1 is the overarching
question—does risk factor assessment or bone measure-
ment testing lead to reduced fracture-related morbidity
and mortality? KQ2, KQ3, KQ4, KQ5, and KQ6 are ques-
tions about intermediate steps along the path, concerning
the accuracy of risk factor assessment and bone measure-
ment testing, potential harms of testing, and treatment of
persons identified as abnormal.
The specification of the presumed relationship be-
tween intermediate, surrogate, and health outcomes in a
visual analytic framework serves a number of useful pur-
poses. It forces the analysts to make explicit, a priori
decisions about the outcomes of interest to arrive at a
recommendation. It allows others to judge whether im-
portant outcomes were overlooked. It makes explicit the
group's opinions about the appropriateness of intermedi-
ate and surrogate outcomes as valid markers of health
outcomes. The proposed interrelationships depicted in
the diagram revealed the analysts’ assumptions about
pathophysiologic relationships. They allow others to
judge whether the correct questions were asked at the
outset.
This type of analytic framework bears a visual resem-
blance to flowcharts, algorithms, and other graphics, but
it differs importantly in content and purpose. The pur-
pose of the visual analytic framework is prospective: the
group defines at the outset the criteria it wishes to con-
sider to arrive at a recommendation. The frameworks
are conceptually different from algorithms. The linkages
define the types of evidence to be reviewed and the out-
comes represent measures of effectiveness, whereas the
‘arrows’ and outcomes in algorithms depict clinical
choices, test results, or pathophysiologic events in the
workup and treatment of patients [15,16].
Filling in the evidence
The linkages in the visual analytic framework provide a
‘road map’ to guide the process of reviewing the evi-
dence. They provide a specific list of questions that need
to be answered by the group to arrive at a recommenda-
tion, though they do not define which types of evidence
should be searched to provide the information. Once
these questions have been answered, the literature re-
view can proceed through an orderly process of search-
ing admissible evidence to find support for the specific
linkages in the analytic framework. The evidence sup-
porting the linkages is often heterogeneous, with some
linkages supported by randomized controlled trials and
others supported by other classes of evidence.
Given the increasing availability of systematic reviews of
different types of studies addressing different questions,
guideline developers should initially search for relevant
systematic reviews for each question as the availability of
Figure 1 Analytical framework and KQs (Keywords). From Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force.
Authors: Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. published in Annals of Internal Medicine, July 5, 2010. Reprinted with permission.
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an up-to-date, high-quality, relevant systematic review
could mitigate the need to undertake a systematic review
de novo. Whitlock et al. provide guidance about the meth-
odological and practical issues that developers need to
consider when using existing systematic reviews in guide-
line development [17].
Completing the analytic logic
Often, the information displayed in the analytic frame-
work is only the starting point for more detailed analysis
of the data. The completed diagram indicates only the
class of evidence that supports a linkage and says little
about the results of the studies, the consistency of the
findings, or the quality of the data. Approaches for
examining the evidence in more detail include the full
range of analytic methods, such as simple narrative sum-
maries, evidence tables, meta-analyses, and modeling. As
a graphics device, the visual analytic framework is not
meant to capture these details. Its role is to identify
where the evidence sits in the analytic logic, not to de-
scribe what the evidence shows.
Writing a clear rationale statement is facilitated by the
information in the analytic framework. The rationale
statement can thereby summarize the benefits, harms,
and other outcomes that were considered; why the out-
comes were considered important (including consider-
ation of patient preferences); the group's assumptions
about the relationship between intermediate and surro-
gate outcomes and health outcomes; and the types of
evidence that the group found in support of the linkages.
If the review found linkages that lack supporting evi-
dence, the rationale statement can speak honestly about
the role that opinion, theory, or clinical experience
played in arriving at a recommendation. This ‘truth in
advertising’ helps ensure that the rationale statement
provides clinicians, policymakers, and other guideline
users with credible information about underlying assump-
tions. It also helps avoid misleading generalizations about
the science, such as claiming that a maneuver is supported
by ‘randomized controlled trials’ when such evidence sup-
ports only one linkage in the rationale. By sharing the
blueprint for the recommendations, the linkages in the
analytic logic allow groups to identify the pivotal assump-
tions about which they disagree.
Finally, by drawing attention to linkages that lack sci-
entific support, the analytic framework highlights the
most important outcomes to be examined by researchers
to establish the effectiveness of a clinical practice. This
information is essential, in an era of limited research
funds, to set priorities and direct outcomes research to-
ward the fundamental questions to be answered. The
outcomes identified in the framework also provide a tem-
plate for testing the efficacy of the guidelines themselves
in research evaluating the effect of guidelines on quality of
care.
Integrating values in guideline development
Recommendations do not emerge directly from the em-
pirical data reviewed by a guideline group. When the sci-
ence clearly indicates substantial net benefit (benefit
minus harms) or that an intervention is clearly ineffective
or harmful, the need to consider values and preferences is
less important. However, two major circumstances occur
commonly in guideline development that require sensitiv-
ity to personal preferences and subjective judgments.
First, when the evidence is unclear, judgments about
the occurrence and effect magnitude of an intervention
often depend on subjective judgments about the quality
of the studies. For example, a number of randomized
controlled trials have evaluated the effectiveness of mam-
mography screening for breast cancer, and a large body of
empirical data about the effect size is available [18]. How-
ever, for two decades, experts with different opinions
about the methods used in the trials have reached differ-
ent conclusions about the quality of the evidence and the
likely mortality reduction from mammography at different
ages [19]. In the presence of scientific uncertainty, judg-
ments based on other considerations often, and some-
times legitimately, take on greater importance. Guideline
developers often consider clinical experience, expert opin-
ion, the health condition in question and its severity, the
potential harms of the intervention, and the potential
harms of inaction. These judgments inevitably color how
groups characterize the evidence and frame recommenda-
tions in the face of uncertainty [20]. In some instances,
groups opt for neutrality, stating that there is insufficient
evidence to make a recommendation [21]. In other cir-
cumstances, as when the condition poses great risk or
there is little potential harm, the group may recommend
the intervention despite inadequate evidence. In the op-
posite circumstance, when concerns about potential
harms are heightened, a group may recommend against
an intervention pending more convincing evidence
[22]. Whatever choice is made, it is best for guideline
developers to be transparent about value judgments
[23]. The rationale for concluding that the evidence is
strong, weak, or equivocal should be explained, pre-
ferably in detail. Concerns about the methods used
for performing studies or evaluating outcomes should
be outlined, both to explain the group’s rationale but
also to guide future research to address limitations in
the evidence. For example, knowing that guideline
groups have recurrently cited contamination of the
control group as a weakness in studies of an inter-
vention will encourage future studies to devise in-
novative methods to address this concern.
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Second, even when the occurrence or effect size is suffi-
ciently clear from the data, the judgment of whether bene-
fits outweigh harms can often be inherently subjective
[24]. In such ‘close calls,’ people faced with the same data
about the probabilities of benefits and harms can reach
different conclusions about net benefit because of the dif-
ferent values, or utilities, they assign to the outcomes
[25,26]. For example, the risk of developing urinary incon-
tinence from radiation therapy for prostate cancer may be
less disconcerting to an oncologist or patient who is fo-
cused on the hazard of the cancer than to a clinician or
patient who is more concerned about quality of life than
life expectancy. These subjective judgments are neither
right nor wrong, but they do influence conclusions about
net benefit and a group’s leanings on whether or not to
recommend an intervention.
Groups have two options for dealing with close calls
that involve difficult tradeoffs. First, they can make the
decision themselves and conclude whether benefits out-
weigh harms. The group, with its in-depth knowledge of
the clinical topic and the underlying science, can infer
how most patients would react if faced with the same in-
formation. Such groups act as a proxy for patients, and
the advantage of this approach is that the group has
mastery of details that are often beyond the ability of
most patients to digest or most busy clinicians to ex-
plain. The disadvantage of this approach is its inherent
paternalism and the risk of misjudgments by the group
[27]. The second option for dealing with close calls is for
the group to eschew a blanket recommendation but to
instead encourage shared or informed decision-making,
in which the patient is encouraged to review the trade-
offs with their clinician and make an individual decision
based on personal preferences [28,29]. When this is
done, the group expressly avoids taking a policy stance.
Its policy is to advise clinicians to engage the patient in
the decision; such groups recognize that the determin-
ation of whether benefits outweigh harms is sensitive to
utilities, a determination that can only be made individu-
ally by the patient and clinician, not by a guideline group
[30]. The advantage of this approach is its respect for
autonomy and individual choice, in which guidelines be-
come a tool for patient empowerment, engagement, and
activation [31,32]. If the group eschews a recommenda-
tion and instead advocates shared decision-making, it is
helpful if the guideline includes details about the content
areas the patient-clinician conversation should cover.
The guideline group is likely to have a clear sense of the
preference-sensitive issues that influence the benefit-
harm tradeoff and can therefore outline the items the
patient and clinician should review, the relevant evi-
dence, the role of decision aids, and other suggestions
for incorporating personal preferences into the decision-
making process.
Incorporating economic considerations in
guideline development
There has been no widely accepted successful way of
incorporating economic considerations into guidelines.
However, the reasons for considering costs are clearly
stated: ‘Health interventions are not free, people are not
infinitely rich, and the budgets of [healthcare] programs are
limited. For every dollar’s worth of healthcare that is con-
sumed, a dollar will be paid. While these payments can be
laundered, disguised or hidden, they will not go away’ [8].
Such opportunity costs are a universal phenomenon. It is
also the case that while considerations of effectiveness may
be applicable across different healthcare systems, considera-
tions of cost and values are more likely to be healthcare
system-specific. Therefore, a cost-effectiveness guideline
may be less transferable than one based solely on clinical
effectiveness.
In the USA, the 1992 IOM report [33] offered the aspir-
ational recommendation that every set of clinical guide-
lines should include information on the cost implications
of the alternative preventive, diagnostic, and management
strategies for each clinical situation. The stated rationale
was that this information would help potential users to
better evaluate the potential consequences of different
practices. However, they then acknowledged that ‘the
reality is that this recommendation poses major meth-
odological and practical challenges.’ Although there is
emerging practical experience, this position has not
really changed. In addition, it has also become recog-
nized that issues of cost are much more likely to be
health system-specific (as compared to the clinical
evidence areas of guideline development) and so, un-
less explicitly mandated—like the UK National Institute
for Health and Clinical Excellence (NICE)—many guide-
line developers do not do this.
Some guideline development organizations (e.g., NICE)
advocate the review of appropriate cost-effectiveness
studies alongside the review of the clinical evidence,
though, in their guideline development manual, they
note that ‘only rarely will the health economic literature
be comprehensive enough and conclusive enough that
no further analysis is required. Additional economic ana-
lyses will usually be needed.’ The available ‘economic
evidence’ may be limited in terms of general applicability
to the specific context of the clinical guideline, but can
be useful in framing the general bounds of cost-
effectiveness of management options for a clinical condi-
tion and providing an explicit source for some of the
assumptions that may have to be made.
The methods of incorporating economic considera-
tions are shaped by the methods of guideline develop-
ment [34]. Early on in the development of each of the
guidelines, there is a fundamental decision to be made
about how to summarize the data and whether or not
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there are common outcomes across studies. If common
outcomes are available, then it may be possible to use
quantitative techniques (meta-analysis or meta-regression)
leading to summary relative and absolute estimates of
benefit, and it may then be possible to formally combine
the elements of effectiveness and cost into a summary
cost-effectiveness statistic. With relatively broad clinical
areas (e.g., the management of type 2 diabetes), it is more
difficult to do this, whereas for narrower areas (e.g., choos-
ing a drug to treat depression) it is may be more feasible.
If the evidence summary is to be qualitative (a narra-
tive review of studies) the data can be set out in ways
that facilitate easy comparison between studies by using
common descriptors (e.g., study design, study popula-
tion, intervention, duration of intervention) using evi-
dence tables. However, under these circumstances it may
not be possible to make estimates of cost-effectiveness
unless the evidence summary is dominated by one study
with appropriate outcomes. For guidelines that use
qualitative evidence summary methods (not amenable to
meta-analysis), it is usually only possible to present cost
data alongside the evidence of clinical effectiveness allow-
ing a reader to make their own judgments about the rela-
tive weight to be ascribed to these two dimensions of
evidence. It is possible to make cost minimization state-
ments such as: ‘as the treatments appear equivalent clini-
cians should offer the cheapest preparation that patients
can tolerate and comply with.’
For guidelines focused on a single decision, it may be
possible to incorporate economic data into a formal deci-
sion analysis framework. Traditionally, it is the province of
health economics to model (combine, adjust, extrapolate,
represent) intermediate clinical outcome data and data
from other sources to explore the overall costs and conse-
quences of treatment alternatives. In principle, it is pos-
sible to map clinical data onto generic quality of life
scores, model the advancement of disease and produce
cost per quality-adjusted life year (QALY) estimates for
each treatment decision. However, such a process con-
trasts with the above methods in a number of ways. First,
although they may have a role in informing the questions,
values, and assumptions that go into a model, there is no
clear role for a multi-disciplinary guideline development
group in deriving recommendations around the clinical
decision—the ‘right decision’ is produced by the model.
Second, the data are aggregated into a single metric, the
constituent elements of which (and their associated uncer-
tainty) are not transparent. Third, the complexity of mod-
eling a single decision is often such that the viability of the
method to deal with more complex clinical decisions,
which have multiple interdependencies, has to be ques-
tioned. Therefore, the appropriate application of a deci-
sion analysis-driven guideline is currently unclear and a
question for further research.
Guideline recommendations
Wording recommendations
An important aspect of developing recommendations
that will favorably influence care is the wording used for
the recommendations. McDonald [35] and others have
lamented the existence of recommendations that are
vague or nonspecific, and that use what they call ‘weasel
words,’ as in ‘patients with< condition name> should be
offered the intervention if clinically appropriate’ or ‘clini-
cians should follow-up patients given the intervention
every four weeks, or sooner if necessary’ because clini-
cians trying to use the guideline may have difficulty, or
themselves be uncertain about, what constitutes ‘clinic-
ally appropriate’ or ‘if necessary.’ Grol et al. found that
Dutch general practitioners followed guideline recom-
mendations that were vague or nonspecific 35% of the
time, while ‘clear’ recommendations were followed 67%
of the time [36]. An experimental study using vignettes
of patients with back pain found that specific guidelines
produced more appropriate and less inappropriate
orders for electro-diagnostic tests than did vague guide-
lines [37]. Michie and Johnston, using evidence from
psychological research, went so far as to conclude that
the ‘most cost effective intervention to increase the im-
plementation of guidelines is rewriting guidelines in be-
haviorally specific terms’ [38].
However, a standard for wording of recommendation
does not exist [39]. The lack of a standard is reflected in
the results of a comprehensive evaluation of over 1,275
randomly selected recommendations (out of over 7527)
from the National Guideline Clearinghouse by Hussain
et al. [40]. Recommendations were presented with great
inconsistency within and across guidelines, and 31.6% did
not present executable actions. Over one-half (52.6%) did
not indicate the strength of the recommendation.
The Editorial Board of the National Guideline Clear-
inghouse ‘encourages [guideline] developers to formulate
recommendation statements that are ‘actionable’ and
that employ active voice, rather than passive voice’ [41].
In the UK, NICE describes that recommendations should
be clear and concise, but include sufficient information that
they can be understood without reference to other support-
ing material (National Institutes for Health and Clinical
Excellence Handbook) [42].
Clarity and precision in guidelines are desirable not
only to facilitate implementation by clinicians and patients
but also to be incorporated into decision support tools (e.g.,
prompts used by electronic medical records, standing
orders, checklists) to facilitate guideline implementation.
However, guideline developers who closely follow evidence-
based methods in formulating guidelines may find the sci-
ence inadequate to justify such precision. Under such
circumstances, ambiguity may more faithfully reflect adher-
ence to the data than would spurious precision. For
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example, the evidence indicates that Papanicolaou smears
are effective every one to three years, and that mammo-
graphic screening can reduce mortality whether it is per-
formed annually or every other year [43]. For some
screening tests, there is inadequate evidence to specify any
interval or to define the risk groups for which screening is
appropriate. When research has not determined that one
interval is effective and another is not, arbitrarily fabricat-
ing a precise answer may satisfy demands for ‘clear’ guide-
lines but it departs from the evidence. It also exposes
clinicians and patients to potential harm by proscribing
care practices that may be entirely reasonable. Evidence-
based guideline developers therefore always struggle with
the tension between providing guidance that is as clear
and precise as possible and the need to not reach beyond
the supporting science.
The little evidence that does exist suggests that consu-
mers of healthcare recommendations prefer knowing
about the underlying quality of evidence, and that sym-
bols to indicate the strength of recommendations are
more informative than numbers [44,45]. Based on their
review of the NGC database, Hussain et al. suggest six
criteria to be followed in the presentation and formula-
tion of recommendations (Table 1).
What approaches to grading the quality of evidence and
strength of recommendations exist?
Grading of healthcare recommendations began with the
Canadian Task Force on the Periodic Health Examination
over three decades ago [46]. In 2002, AHRQ published a
systematic review of existing systems to grade the quality
of evidence and strength of recommendations [47]. The
AHRQ review considered 40 systems until the year 2000
that addressed grading the strength of a body of evidence.
The important domains and elements for the systems to
grade the strength of evidence that the authors agreed on
were quality (the aggregate of quality ratings for individual
studies, predicated on the extent to which bias was mini-
mized), quantity (magnitude of effect, numbers of studies,
and sample size or power), and consistency (for any given
topic, the extent to which similar findings are reported
using similar and different study designs).
In 2005, the Canadian Optimal Medication Prescribing
and Utilization Service (COMPUS), a department within
the Canadian Agency for Drugs and Technology in Health
(CADTH), used a detailed process to evaluate and select
an evidence grading system and expanded the work by
AHRQ (while accepting it) until the year 2005 [48]. Nearly
50 evidence grading systems were identified from 11 re-
view articles. Experts in evidence evaluation methodology
helped identify an additional 10 instruments or systems
not included in the list of identified grading systems. The
identified instruments and systems were evaluated using
the AHRQ evaluation grids. The highest scoring instru-
ments were the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) working group and
the SIGN approaches [48]. A second round of expert con-
sultation and stakeholder input from all interested parties
confirmed the selection of these instruments. However,
SIGN—while providing a detailed system for assessing the
quality of individual studies—provided no clear guidance
for summarizing the quality of evidence across studies and
for moving from the research evidence to recommenda-
tions. SIGN therefore recently adopted GRADE that laid
out these steps more explicitly.
GRADE
A number of publications describe the GRADE approach
and its development [44,49-57]. The GRADE working
group (www.gradeworkinggroup.org) [49] emphasizes the
link between the quality of a body of evidence and the
recommendation, but recognizes that other factors be-
yond the quality of evidence contribute to the strength of
a recommendation, such as patient values and preferences
[58,59].
GRADE considers eight factors in the assessments of
the quality of evidence for each important outcome
(Table 2). Concerns about any of five factors can lower
the confidence in an estimate of effect and study quality:
study design and execution (risk of bias); consistency of
the evidence across studies; directness of the evidence
(including concepts of generalizability, transferability
and external validity); the precision of the estimate of
the effect; and publication bias. The presence of any of
Table 1 Criteria to be followed in the presentation and formulation of recommendations
1. Identify the critical recommendations in guideline text using semantic indicators (such as ‘The Committee recommends. . .’ or ‘Whenever X, Y, and
Z occur clinicians should . . .’) and formatting (e.g., bullets, enumeration, and bold face text).
2. Use consistent semantic and formatting indicators throughout the publication.
3. Group recommendations together in a summary section to facilitate their identification.
4. Do not use assertions of fact as recommendations. Recommendations must be decidable and executable.
5. Avoid embedding recommendation text deep within long paragraphs. Ideally, recommendations should be stated in the first (topic) sentence of
the paragraph and the remainder of the paragraph can be used to amplify the suggested guidance.
6. Clearly and consistently assign evidence quality and recommendation strength in proximity to each recommendation and distinguish between
the distinct concepts of quality of evidence and strength of recommendation.
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the following three factors can increase the quality of
evidence: a strong or very strong association; a dose-
effect relationship; and all plausible residual confounding
may be working to reduce the demonstrated effect or in-
crease the effect if no effect was observed. The overall
quality of evidence is determined by the lowest quality
of evidence for each of the critical outcomes. However,
when outcomes point in the same direction (all critical
outcomes suggesting benefit), then the overall quality of
evidence reflects the quality of the better evidence (e.g.,
two critical outcomes showing convincing benefit are of
low quality and a third of very low quality, the overall
quality is not reduced from low to very low).
A substantial conceptual difference between GRADE
and other approaches is the handling of expert opinion.
GRADE specifically acknowledges that expertise is
required for interpretation of any form of evidence
(‘judgments’) but considers that opinion is an interpret-
ation of—sometimes unsystematic—evidence, but not a
form of evidence.
Factors that influence recommendations
Four factors influence whether a panel makes a recom-
mendation for or against a management strategy. These
four factors include: the quality of the available support-
ing body of evidence; the magnitude of the difference
between the benefits and undesirable downsides or
harms; the certainty about or variability in values and
preferences of patients; and the resource expenditure
associated with the management options.
Quality of evidence
The quality of evidence reflects the confidence or certainty
in the estimates of effects related to an outcome. If guide-
line panels are uncertain of the magnitude of the benefits
and harms of an intervention, it is unlikely they can make a
strong recommendation for that intervention (see section
on quality of evidence). Thus, even when there is an ap-
parent large gradient in the balance of advantages and
disadvantages, guideline developers will be appropriately
reluctant to offer a strong recommendation for an inter-
vention if the quality of the evidence is low.
The balance between benefits and undesirable downsides
When the benefits of following the recommendation
clearly outweigh the downsides, it is more likely that the
recommendation will be strong. When the desirable and
undesirable consequences are closely balanced, a weaker
recommendation is warranted. While most original stud-
ies and systematic reviews present the magnitudes of ef-
fect of outcomes in relative terms (e.g., relative risk,
hazard ratio, odds ratio), weighing the magnitude of the
difference between the benefits and downsides to de-
velop a recommendation also requires the knowledge of
the likely absolute effects for a specific population or
situation. If the guideline panel judges that the balance
between desirable and undesirable effects varies by base-
line risk, it can issue separate recommendations for
groups with different baselines risks when tools for risk
stratification are available for the guideline users [60,61].
Often, when values and preferences or attitude towards
the resource use may differ from those assumed by
guideline developers, patients, clinicians, and policy
makers may choose to examine the magnitude of effects
of management options on the outcomes of interest
themselves, rather than relying on judgments of those
making the recommendation.
Uncertainty or variability of patient values and
preferences
Different patients can take different views about what
outcome constitutes benefit or harm and clinicians’
understanding of importance of particular outcomes for
patients can differ from that of the patients. Explicit
Table 2 A summary of the GRADE approach to grading the quality of evidence for each outcome
Source of body
of evidence
Initial rating
of quality
Factors that
may decrease
the quality
Factors that may increase the quality Final quality
of a body of
evidence *
Randomised
trials
High 1. Risk of bias 1. Large effect High
2. Inconsistency 2. Dose–response ( or A)
3. Indirectness 3. All plausible residual confounding would reduce
the demonstrated effect or would suggest a
spurious effect if no effect was observed
Moderate
4. Imprecision ( or B)
Observational
studies
Low 5. Publication
bias
Low
( or C)
Very low
( or D)
*Quality of evidence definitions.
High: Further research is very unlikely to change confidence in the estimate of effect.
Moderate: Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.
Low: Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.
Very low: Any estimate of effect is very uncertain.
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consideration of patients’ values and preferences in
making recommendations stems from acknowledge-
ment of patients’ liberty (autonomy). Alternative man-
agement strategies always have associated advantages
and disadvantages and thus a trade-off is always neces-
sary. How patients and guideline panel members value
particular benefits, risks, and inconvenience is critical to
any recommendation and its strength. However, data
about patients’ preferences and values are often limited.
GRADE urges guideline panels to state explicitly what
values and preferences they considered and what weight
they placed on each outcome. This transparent explan-
ation facilitates the interpretation of recommendations,
especially weak ones for which the best course of action
is less certain.
Costs or resource utilization
One could consider resource utilization as one of the
outcomes when balancing positive and negative conse-
quences of competing management strategies. However,
as was mentioned above, costs are much more variable
over time and geographic areas than are other outcomes.
In addition, the implications of the utilized resource vary
widely. For example, a year’s prescription of a drug may
pay for a single nurse’s salary in the United States, ten
nurses’ salaries in Romania, and thirty nurses’ salaries in
India. Therefore, while higher costs will reduce the likeli-
hood of a strong recommendation in favor of a particular
intervention, the context of the recommendation will be
critical. In considering resource allocation, those making
recommendations must be very specific about the setting
to which a recommendation applies and the perspective
they took, i.e., that of a patient, a third party payer or soci-
ety as a whole.
Making recommendations
Those making recommendations may have higher or
lower confidence that following their recommendation
will do more good than harm across the range of
patients for whom the recommendation is intended [62].
They inform users of guidelines (e.g., clinicians, patients
and their family members, policy makers) about the
degree of their confidence by specifying the strength of
recommendations. While in reality the balance between
desirable and undesirable consequences is a continuum,
the GRADE approach uses two grades of the strength of
recommendations—strong or weak (also known as con-
ditional)—reflecting the confidence in the clarity of that
balance or lack thereof (Table 3). This dichotomy serves
to simplify the message, and improve understanding and
communication. In various guidelines following the
GRADE approach words other than ‘weak’ have been
used to express the lower confidence in the balance of
benefits and downsides, e.g., ‘conditional,’ ‘qualified,’ or
‘discretionary.’
Sometimes, authors of guidelines formulate their
recommendations only as statements about the available
evidence (e.g., chromones are effective in the treatment
of allergic rhinitis), but do not explicitly specify what ac-
tion should follow (e.g., should chromones be used in
treatment of allergic rhinitis, given all other available
treatment options?) [40]. GRADE suggests phrasing
recommendations in an active voice as clear indications
what specific action should follow. For example, many
guidelines developed following the GRADE approach
worded their recommendations as ‘we recommend . . .’
Table 3 Implications of the two grades of strength of recommendations in the GRADE approach
Target group Strong recommendations* Conditional (weak) recommendations
Patients Most people in your situation would want the
recommended course of action and only a small
proportion would not
The majority of people in your situation would want the
recommended course of action, but many would not
Clinicians Most patients should receive the recommended course of
action
Recognise that different choices will be appropriate for
different patients and that you must make greater effort
with helping each patient to arrive at a management
decision consistent with his or her values and preferences
Decision aids and shared decision making are particularly
useful
Policy makers and
developers of quality
indicators
The recommendation can be adopted as a policy in most
situations
Policy making will require substantial debate and
involvement of many stakeholders
* Strong recommendations based on high quality evidence will apply to most patients for whom these recommendations are made, but they may not apply to all
patients in all conditions; no recommendation can take into account all of the often-compelling unique features of individual patients and clinical circumstances.
Table 4 Criteria to be met for a recommendation for use
of interventions in the context of research to be sensible
1. There must be important uncertainty about the effects of the
intervention (e.g., low or very low quality evidence for either or both
the desirable and undesirable consequences.
2. Further research must have the potential to reduce that uncertainty
at a reasonable cost.
3. The potential benefits and savings of reducing the uncertainty
outweigh the potential harms and costs of either using or not using
the intervention based on currently available evidence
Woolf et al. Implementation Science 2012, 7:61 Page 9 of 12
http://www.implementationscience.com/content/7/1/61
and ‘we suggest . . .’ to distinguish strong from weak
recommendations. Alternatives for strong recommenda-
tions include ‘clinicians should . . .’ while weak recommen-
dations can be phrased as ‘clinicians might . . .’ or ‘we
conditionally recommend . . ..’ Expressing the strength of
recommendations may become even more challenging
when they are formulated in languages other than English.
Should guideline panels make recommendations in the
face of very low-quality evidence?
In the face of very low-quality evidence, there is broad
agreement that the option of not making a recommen-
dation should be included for all guideline panels. How-
ever, higher-quality evidence may never be obtained, and
physicians need guidance regardless of the quality of the
underlying evidence. Ideally, guideline panels should use
their best judgments to make specific and unambiguous
recommendations (albeit conditional ones in the face of
very low quality evidence) and transparently lay out the
judgments they make. Some groups maintain that no
recommendations should be made when the evidence is
considered ‘insufficient.’ The USPSTF uses an ‘insuffi-
cient evidence to make a recommendation’ category. It is
argued that it is too risky for a guideline panel to make a
recommendation on low- or very low-quality when there
is a substantial risk the panel may be wrong.
Research recommendations
There are not well-established criteria for guiding panels
to make the determination of whether research should
be done. Nonetheless, the criteria in Table 4 must be
met for a recommendation for use of interventions in
the context of research to be sensible [63,64]. The re-
search recommendations should be detailed regarding
the specific research questions that should be addressed,
particularly which patient-important outcomes should
be measured, and other relevant aspects of what research
is needed [65]. Because the target audience for most
guidelines is clinicians, the recommendations for research
may seem misplaced and distracting among the recom-
mendations related to practice. If this is the case, research
recommendations could be placed in an appendix or spe-
cial sections in the guideline directed at researchers and
research funding agencies. A similar format decision
should affect the design of executive summaries.
Summary
In this paper, we have discussed the issues of identifying
and synthesizing evidence: deciding what type of evi-
dence and outcomes to include in guidelines; integrating
values into a guideline; incorporating economic consid-
erations; synthesis, grading, and presentation of evi-
dence; and moving from evidence to recommendations.
In the third and final paper in the series, we will discuss
the issues of: reviewing, reporting, and publishing guide-
lines; updating guidelines; and the two emerging issues
of enhancing guideline implementability and how guide-
lines approach dealing with patients with co-morbid
conditions.
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